Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Diabetes

Journal Scan / Research · December 13, 2024

Effect of SGLT2 Inhibitors on Cardiovascular Outcomes and Mortality Across the Spectrum of Kidney Disease

Diabetes Research and Clinical Practice

 

Additional Info

Diabetes Research and Clinical Practice
SGLT2 inhibitors, cardiovascular outcomes, and mortality across the spectrum of kidney disease: A systematic review and meta-analysis
Diabetes Res. Clin. Pract. 2024 Nov 18;218(xx)111933, BF Spiazzi, GF Piccoli, LF Wayerbacher, JPN Lubianca, BG Scalco, MH Scheffler, BL Fraga, V Colpani, F Gerchman

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading